Get the Stockscreener App
73.93
0.88%
-0.66
Henry Schein Inc stock is traded at $73.93, with a volume of 1.79M.
It is down -0.88% in the last 24 hours and up +1.22% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$74.59
Open:
$74.83
24h Volume:
1.79M
Relative Volume:
1.37
Market Cap:
$8.48B
Revenue:
$13.18B
Net Income/Loss:
$419.00M
P/E Ratio:
22.61
EPS:
3.2704
Net Cash Flow:
$521.00M
1W Performance:
-4.66%
1M Performance:
+1.22%
6M Performance:
+16.98%
1Y Performance:
+14.69%
1-Day Range:
$73.40
$74.90
1-Week Range:
$72.78
$78.02
52-Week Range:
$61.95
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
73.93 | 8.48B | 13.18B | 419.00M | 521.00M | 3.2704 |
MCK
Mckesson Corp
|
814.02 | 99.71B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
304.00 | 59.14B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
195.24 | 45.94B | 250.74B | 1.55B | 4.39B | 6.5391 |
AHG
Akso Health Group Adr
|
2.14 | 1.83B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Melville Employees Assemble 1,500 Hygiene Kits For Families Of Sick Children - Patch
Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Rating of "Hold" from Analysts - MarketBeat
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
On Our Island: Long Island nonprofits and businesses support mental health and cancer research - Long Island Business News
Vanguard Capital Management (HSIC) reports 6.36% ownership in Henry Schein - Stock Titan
Henry Schein Stock (US42548G1040): Set to Report Q1 2026 Results Today - AD HOC NEWS
Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound? - MSN
Henry Schein Inc (HSIC) Stock Down 3.0% -- Now Undervalued? GF S - GuruFocus
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Greenlight Capital Adds Henry Schein Shares Amid Leadership Transition - HarianBasis.co
Henry Schein Inc. (HSIC): David Einhorn Is Buying This Health Stock - Yahoo Finance
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Henry Schein One Launches MCP Layer - Dentistry Today
Henry Schein shrinks board as long-serving chairman retires - MSN
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
What to expect from Henry Schein’s Q1 2026 earnings report - MSN
Dentrix Ascend Opens Its MCP Layer, Bringing AI Agents and a Custom Build Platform to Dental Practices - 01net
Dental offices can query records in plain language as AI agents go live - Stock Titan
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Here's How Henry Schein Is Placed Ahead of Q1 Earnings - Yahoo Finance
Henry Schein (HSIC) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Stifel Downgrades Henry Schein (HSIC) - MSN
HSIC Stock Jumps on Q3 Earnings and Revenue Beat, '25 Outlook Up - MSN
Henry Schein (NASDAQ:HSIC) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET - The National Law Review
Henry Schein Q1 2025 Earnings Preview - MSN
Morgan Stanley Adjusts Price Target on Henry Schein to $64 From $61, Maintains Underweight Rating - marketscreener.com
Morgan Stanley Maintains Henry Schein(HSIC.US) With Sell Rating, Raises Target Price to $64 - Moomoo
Henry Schein downgraded at Stifel on market share concerns - MSN
quip Announces Supplier Package Agreement with Henry Schein for Availability of the Ultra Next-Generation Smart Sonic Toothbrush to Dental Professionals Nationwide - Dentistry Today
HSIC (Henry Schein Inc.) edges past Q4 2025 EPS estimates, shares climb 2.1 percent on positive investor reception.Senior Analyst Forecasts - UBND thành phố Hải Phòng
Henry Schein Board Reset Raises Questions For Valuation And Capital Decisions - Yahoo Finance
HSIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Henry Schein (HAM:HS2) Short-term investments - GuruFocus
Henry Schein to Release Q1 2026 Results - Dentistry Today
Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET - Business Wire
How Henry Schein’s Board Overhaul and Bergman’s Exit At Henry Schein (HSIC) Has Changed Its Investment Story - simplywall.st
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 14.17% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Is Henry Schein (HSIC) stock fairly priced today (+2.10%) 2026-04-18Reversal Setup - Cổng thông tin điện tử Tỉnh Sơn La
Henry Schein (NASDAQ:HSIC) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Why Henry Schein (HSIC) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Here's why Henry Schein (HSIC) is a strong value stock - MSN
Henry Schein (NASDAQ:HSIC) Upgraded by Citigroup to Strong-Buy Rating - MarketBeat
BTIG initiates coverage of Henry Schein (HSIC) with neutral recommendation - MSN
Here's Why Henry Schein (HSIC) is a Strong Value Stock - Yahoo Finance
BTIG initiates Henry Schein stock coverage with Neutral on modest growth - Investing.com
Citigroup initiates coverage of Henry Schein (HSIC) with buy recommendation - MSN
Citigroup Initiates Henry Schein at Buy With $100 Price Target - Moomoo
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):